You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database

Article info

Article menu

Download PDFPDF

Rheumatoid arthritis
Original research
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database

Authors

  • Raphaele Seror Service de Rhumatologie, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Université Paris-Saclay, FHU CARE, Le Kremlin-Bicetre, FranceINSERM UMR 1184, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicetre, France PubMed articlesGoogle scholar articles
  • Alexandre Lafourcade Centre de Pharmacoépidémiologie (Cephepi), AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Yann De Rycke Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Paris, FranceInstitut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, France PubMed articlesGoogle scholar articles
  • Sandrine Pinto Institut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, France PubMed articlesGoogle scholar articles
  • Johann Castaneda Centre de Pharmacoépidémiologie (Cephepi), AP-HP. Sorbonne Université, Hôpital Universitaire Pitié Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Bruno Fautrel Institut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, FranceService de Rhumatologie, Sorbonne Université, AP-HP.Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France PubMed articlesGoogle scholar articles
  • Xavier Mariette Service de Rhumatologie, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Université Paris-Saclay, FHU CARE, Le Kremlin-Bicetre, FranceINSERM UMR 1184, Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicetre, France PubMed articlesGoogle scholar articles
  • Florence Tubach Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1901, Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Paris, FranceInstitut Pierre Louis d'epidemiologie, Sorbonne University, INSERM UMR-S 1136, Paris, Francedelete this affiliaton, Paris, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Raphaele Seror; raphaele.seror{at}aphp.fr
View Full Text

Citation

Seror R, Lafourcade A, De Rycke Y, et al
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
RMD Open 2022;8:e002139. doi: 10.1136/rmdopen-2021-002139

Publication history

  • Received December 2, 2021
  • Accepted May 22, 2022
  • First published June 23, 2022.
Online issue publication 
June 27, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.